# PepBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pepbio

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.pdbio.com.cn
- Latest round: Series A (Dec 19, 2025)
- Investors on record: 1

## About

Founded in 2021 and based in Chengdu, China, Chengdu Pede Biomedical Co., Ltd., trading as PepBio, operates as a biopharmaceutical developer dedicated to building a large-scale library of natural active peptides. The company was co-founded by the professor of the Hunan University, CEO of Silver Valley Pharmaceuticals and research and development director of Jiuzitang. Lai Ern, the chief scientist of the company, was deputy director of Kunming Institute of Zoology, Chinese Academy of Sciences. In December 2025, PepBio closed Series A funding from new investor Shangshan Capital.
The company developed and built a natural active peptide library, a high-throughput plus cloud computing screening platform and an AI artificial intelligence platform. These products enable peptide drug screening and development, and the development of innovative peptide drugs. The company has established a technical system for active peptides of animal venom, utilizing genome, transcriptome, peptidome and other multi-omics technologies to conduct histological analysis of toxic animal samples, and then collect highly active peptide sequences.
The company generates revenue by doing R&D, and providing innovative peptide drugs and other related products.
The Series A funding raised in December 2025 will be used to advance the development of core pipelines for pain management, cardiovascular and cerebrovascular diseases, and respiratory diseases, while also deploying large-scale artificial intelligence (AI)-assisted peptide drug development technology.

## Funding rounds

- Series A, Dec 19, 2025 — Shangshan Capital

## Investors

- Shangshan Capital (https://capitalatlas.ai/funds/shangshan-capital) — Series A